References
- Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74; http://www.ncbi.nlm.nih.gov/pubmed/20811384; http://dx.doi.org/10.1038/nrd3229
- Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. Scfv antibody: Principles and clinical application. Clin Dev Immunol 2012; 2012:980250; http://www.ncbi.nlm.nih.gov/pubmed/22474489; PMID:22474489; http://dx.doi.org/10.1155/2012/980250
- Riethmuller G. Symmetry breaking: Bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012; 12:12; http://www.ncbi.nlm.nih.gov/pubmed/22896757; PMID:22896757
- Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; http://www.ncbi.nlm.nih.gov/pubmed/24094861; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
- Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, Niederfellner G, Sustmann C. Molecular characterization of novel trispecific erbb-cmet-igf1r antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25:551-9; http://www.ncbi.nlm.nih.gov/pubmed/22936109; http://dx.doi.org/10.1093/protein/gzs048
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified t cells: Cars take the front seat for hematologic malignancies. Blood 2014; 123:2625-35; http://www.ncbi.nlm.nih.gov/pubmed/24578504; PMID:24578504; http://dx.doi.org/10.1182/blood-2013-11-492231
- Bazan J, Calkosinski I, Gamian A. Phage display–a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother 2012; 8:1817-28; http://www.ncbi.nlm.nih.gov/pubmed/22906939; PMID:22906939; http://dx.doi.org/10.4161/hv.21703
- Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61; http://www.ncbi.nlm.nih.gov/pubmed/21846562; PMID:21846562; http://dx.doi.org/10.1016/B978-0-12-386483-3.00004-5
- Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol 2013; 31:612-20; http://www.ncbi.nlm.nih.gov/pubmed/23932102; http://dx.doi.org/10.1016/j.tibtech.2013.07.002
- Jefferis R. Aggregation, immune complexes and immunogenicity. mAbs 2011; 3:503-4; http://www.ncbi.nlm.nih.gov/pubmed/22123066; PMID:22123066; http://dx.doi.org/10.4161/mabs.3.6.17611
- Baneyx F, Mujacic M. Recombinant protein folding and misfolding in escherichia coli. Nat Biotechnol 2004; 22:1399-408; http://www.ncbi.nlm.nih.gov/pubmed/15529165; PMID:15529165; http://dx.doi.org/10.1038/nbt1029
- Bondos SE, Bicknell A. Detection and prevention of protein aggregation before, during, and after purification. Anal Biochem 2003; 316:223-31; http://www.ncbi.nlm.nih.gov/pubmed/12711344; http://dx.doi.org/10.1016/S0003-2697(03)00059-9
- Lu ZJ, Deng SJ, Huang DG, He Y, Lei M, Zhou L, Jin P. Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem 2012; 3:187-96; http://www.ncbi.nlm.nih.gov/pubmed/23275803; PMID:23275803; http://dx.doi.org/10.4331/wjbc.v3.i12.187
- Arteaga CL, Engelman JA. Erbb receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25:282-303; http://www.ncbi.nlm.nih.gov/pubmed/24651011; http://dx.doi.org/10.1016/j.ccr.2014.02.025
- Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27; http://www.ncbi.nlm.nih.gov/pubmed/18784101; PMID:18784101; http://dx.doi.org/10.1056/NEJMoa0802656
- Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17; http://www.ncbi.nlm.nih.gov/pubmed/19339720; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
- Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Final results from prime: Randomized phase iii study of panitumumab with folfox4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:1346-55; http://www.ncbi.nlm.nih.gov/pubmed/24718886; PMID:24718886; http://dx.doi.org/10.1093/annonc/mdu141
- Roskoski R Jr. The erbb/her family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79:34-74; http://www.ncbi.nlm.nih.gov/pubmed/24269963; http://dx.doi.org/10.1016/j.phrs.2013.11.002
- Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods 2001; 248:17-30; http://www.ncbi.nlm.nih.gov/pubmed/11223066; PMID:11223066; http://dx.doi.org/10.1016/S0022-1759(00)00340-9
- Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of egfr antibodies. Mol Cancer Ther 2012; 11:1467-76; http://www.ncbi.nlm.nih.gov/pubmed/22564724; PMID:22564724; http://dx.doi.org/10.1158/1535-7163.MCT-11-1038
- Dudgeon K, Rouet R, Christ D. Rapid prediction of expression and refolding yields using phage display. Protein Eng Des Sel 2013; 26:671-4; http://www.ncbi.nlm.nih.gov/pubmed/23690626; http://dx.doi.org/10.1093/protein/gzt019
- Honegger A, Malebranche AD, Rothlisberger D, Pluckthun A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel 2009; 22:121-34; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19136675; PMID:19136675; http://dx.doi.org/10.1093/protein/gzn077
- Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: Hydrophobic versus electrostatic inter-molecular interactions. mAbs 2015; 7:212-30; http://www.ncbi.nlm.nih.gov/pubmed/25559441; PMID:25559441; http://dx.doi.org/10.4161/19420862.2014.985504
- North B, Lehmann A, Dunbrack RL Jr. A new clustering of antibody cdr loop conformations. J Mol Biol 2011; 406(2):228-56; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21035459
- Jung S, Pluckthun A. Improving in vivo folding and stability of a single-chain fv antibody fragment by loop grafting. Protein Eng 1997; 10:959-66; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9415446; PMID:9415446; http://dx.doi.org/10.1093/protein/10.8.959
- Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, et al. Imgt, the international immunogenetics information system. Nucleic Acids Res 2009; 37:D1006-1012; http://www.ncbi.nlm.nih.gov/pubmed/18978023; PMID:18978023; http://dx.doi.org/10.1093/nar/gkn838
- Ewert S, Honegger A, Pluckthun A. Structure-based improvement of the biophysical properties of immunoglobulin vh domains with a generalizable approach. Biochemistry 2003; 42:1517-28; http://www.ncbi.nlm.nih.gov/pubmed/12578364; PMID:12578364; http://dx.doi.org/10.1021/bi026448p
- Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human fab antibody library based on fixed vh/vl framework pairings with favorable biophysical properties. mAbs 2013; 5:445-70; http://www.ncbi.nlm.nih.gov/pubmed/23571156 https://http://www.landesbioscience.com/journals/mabs/2012MABS0336R.pdf; http://dx.doi.org/10.4161/mabs.24218
- Adolf-Bryfogle J, Xu Q, North B, Lehmann A, Dunbrack RL Jr. Pyigclassify: A database of antibody cdr structural classifications. Nucleic Acids Res 2015; 43:D432-438; http://www.ncbi.nlm.nih.gov/pubmed/25392411 http://nar.oxfordjournals.org/content/43/D1/D432.full.pdf; http://dx.doi.org/10.1093/nar/gku1106
- Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, et al. Crystal structure of the broadly cross-reactive hiv-1-neutralizing fab x5 and fine mapping of its epitope. Biochemistry 2004; 43:1410-7; http://www.ncbi.nlm.nih.gov/pubmed/14769016; PMID:14769016; http://dx.doi.org/10.1021/bi035323x
- Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, et al. Broadly cross-reactive hiv-1-neutralizing human monoclonal fab selected for binding to gp120-cd4-ccr5 complexes. Proc Natl Acad Sci U S A 2002; 99:6913-8; http://www.ncbi.nlm.nih.gov/pubmed/11997472; PMID:11997472; http://dx.doi.org/10.1073/pnas.102562599
- Bork P, Holm L, Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol 1994; 242:309-20; http://www.ncbi.nlm.nih.gov/pubmed/7932691
- Theobald DL, Wuttke DS. Theseus: Maximum likelihood superpositioning and analysis of macromolecular structures. Bioinformatics 2006; 22:2171-2; http://www.ncbi.nlm.nih.gov/pubmed/16777907; PMID:16777907; http://dx.doi.org/10.1093/bioinformatics/btl332
- Ting D, Wang G, Shapovalov M, Mitra R, Jordan MI, Dunbrack RL Jr. Neighbor-dependent ramachandran probability distributions of amino acids developed from a hierarchical dirichlet process model. PLoS Computat Biol 2010; 6:e1000763; http://www.ncbi.nlm.nih.gov/pubmed/20442867; http://dx.doi.org/10.1371/journal.pcbi.1000763
- Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr., Wilson IA, Basler CF. Influenza human monoclonal antibody 1f1 interacts with three major antigenic sites and residues mediating human receptor specificity in h1n1 viruses. PLoS Pathog 2012; 8:e1003067; http://www.ncbi.nlm.nih.gov/pubmed/23236279; PMID:23236279
- Conway P, Tyka MD, DiMaio F, Konerding DE, Baker D. Relaxation of backbone bond geometry improves protein energy landscape modeling. Protein Sci 2014; 23:47-55; http://www.ncbi.nlm.nih.gov/pubmed/24265211; PMID:24265211; http://dx.doi.org/10.1002/pro.2389
- Shapovalov MV, Dunbrack RL Jr. A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. Structure 2011; 19:844-58; http://www.ncbi.nlm.nih.gov/pubmed/21645855; PMID:21645855; http://dx.doi.org/10.1016/j.str.2011.03.019
- Benjwal S, Verma S, Rohm KH, Gursky O. Monitoring protein aggregation during thermal unfolding in circular dichroism experiments. Protein Sci 2006; 15:635-9; http://www.ncbi.nlm.nih.gov/pubmed/16452626; http://dx.doi.org/10.1110/ps.051917406
- Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol 2007; 371:934-47; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17602702; http://dx.doi.org/10.1016/j.jmb.2007.05.011
- Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-48; http://www.ncbi.nlm.nih.gov/pubmed/9367782; PMID:9367782; http://dx.doi.org/10.1006/jmbi.1997.1354
- Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic igg antibodies. mAbs 2011; 3:243-52; http://www.ncbi.nlm.nih.gov/pubmed/21406966; PMID:21406966; http://dx.doi.org/10.4161/mabs.3.3.15234
- Weaver-Feldhaus JM, Miller KD, Feldhaus MJ, Siegel RW. Directed evolution for the development of conformation-specific affinity reagents using yeast display. Protein Eng Des Sel 2005; 18:527-36; http://www.ncbi.nlm.nih.gov/pubmed/16186140; http://dx.doi.org/10.1093/protein/gzi060
- Yang Y, Guo Q, Xia M, Li Y, Peng X, Liu T, Tong X, Xu J, Guo H, Qian W, et al. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. mAbs 2015; 7:440-50; http://www.ncbi.nlm.nih.gov/pubmed/25679409; PMID:25679409
- Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24:155-61; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19409036; PMID:19409036; http://dx.doi.org/10.1089/cbr.2009.0627
- Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain fv antibodies. Cancer Res 1998; 58:485-90; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9458094; PMID:9458094
- Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbb-2 single-chain fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263:551-67; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8918938; PMID:8918938; http://dx.doi.org/10.1006/jmbi.1996.0598
- Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012; 503:255-68; http://www.ncbi.nlm.nih.gov/pubmed/22230572; PMID:22230572; http://dx.doi.org/10.1016/B978-0-12-396962-0.00010-0
- Prassler J, Steidl S, Urlinger S. In vitro affinity maturation of hucal antibodies: Complementarity determining region exchange and rapmat technology. Immunotherapy 2009; 1:571-83; http://www.ncbi.nlm.nih.gov/pubmed/20635988; PMID:20635988
- Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr 2009; 67:340-52; http://www.ncbi.nlm.nih.gov/pubmed/19695370; PMID:19695370; http://dx.doi.org/10.1016/j.pharma.2009.05.008
- Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12498801; PMID:12498801; http://dx.doi.org/10.1016/S0022-2836(02)01237-8
- Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185her2 antibody 4d5 and comparison with molecular modeling. J Mol Biol 1993; 229:969-95; http://www.ncbi.nlm.nih.gov/pubmed/8095303 http://ac.els-cdn.com/S0022283683710995/1-s2.0-S0022283683710995-main.pdf?_tid=c457f9de-11e1-11e4-8422-00000aab0f26&acdnat=1406062389_b5802c5bea05162f9e5b0d04ca8d4ac5; http://dx.doi.org/10.1006/jmbi.1993.1099
- Lo BK. Antibody humanization by cdr grafting. Methods Mol Biol 2004; 248:135-59; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14970494; PMID:14970494
- Winter G, Harris WJ. Humanized antibodies. Trends Pharmacol Sci 1993; 14:139-43; http://www.ncbi.nlm.nih.gov/pubmed/8212307; http://dx.doi.org/10.1016/0165-6147(93)90197-R
- Carter P, Fendly BM, Lewis GD, Sliwkowski MX. Development of herceptin. Breast Dis 2000; 11:103-11; http://www.ncbi.nlm.nih.gov/pubmed/15687596; PMID:15687596
- Worn A, Auf der Maur A, Escher D, Honegger A, Barberis A, Pluckthun A. Correlation between in vitro stability and in vivo performance of anti-gcn4 intrabodies as cytoplasmic inhibitors. J Biol Chem 2000; 275:2795-803; http://www.ncbi.nlm.nih.gov/pubmed/10644744; PMID:10644744; http://dx.doi.org/10.1074/jbc.275.4.2795
- Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59; http://www.ncbi.nlm.nih.gov/pubmed/7878478; PMID:7878478
- Poshusta TL, Katoh N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M. Thermal stability threshold for amyloid formation in light chain amyloidosis. Int J Mol Sci 2013; 14:22604-17; http://www.ncbi.nlm.nih.gov/pubmed/24248061; PMID:24248061; http://dx.doi.org/10.3390/ijms141122604
- Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with al amyloidosis. PLoS One 2009; 4:e5169; http://www.ncbi.nlm.nih.gov/pubmed/19365555; PMID:19365555; http://dx.doi.org/10.1371/journal.pone.0005169
- Shin TM, Isas JM, Hsieh CL, Kayed R, Glabe CG, Langen R, Chen J. Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. Mol Neurodegener 2008; 3:16; http://www.ncbi.nlm.nih.gov/pubmed/18939994; PMID:18939994; http://dx.doi.org/10.1186/1750-1326-3-16
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped blast and psi-blast: A new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402; http://www.ncbi.nlm.nih.gov/pubmed/9254694; PMID:9254694; http://dx.doi.org/10.1093/nar/25.17.3389
- Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006; 281:15829-36; http://www.ncbi.nlm.nih.gov/pubmed/16597622; PMID:16597622; http://dx.doi.org/10.1074/jbc.M600697200
- Kratzin HD, Palm W, Stangel M, Schmidt WE, Friedrich J, Hilschmann N. [the primary structure of crystallizable monoclonal immunoglobulin igg1 kol. Ii. Amino acid sequence of the l-chain, gamma-type, subgroup i]. Biol Chem Hoppe-Seyler 1989; 370:263-72; http://www.ncbi.nlm.nih.gov/pubmed/2713105; PMID:2713105; http://dx.doi.org/10.1515/bchm3.1989.370.1.263
- Yang Z, Lasker K, Schneidman-Duhovny D, Webb B, Huang CC, PettersenEF, Goddard TD, Meng EC, Sali A, Ferrin TE. Ucsf chimera, modeller, and imp: An integrated modeling system. J Struct Biol 2012; 179:269-78; http://www.ncbi.nlm.nih.gov/pubmed/21963794; PMID:21963794; http://dx.doi.org/10.1016/j.jsb.2011.09.006
- Krivov GG, Shapovalov MV, Dunbrack RL Jr. Improved prediction of protein side-chain conformations with scwrl4. Proteins 2009; 77:778-95; http://www.ncbi.nlm.nih.gov/pubmed/19603484; PMID:19603484; http://dx.doi.org/10.1002/prot.22488
- Sircar A, Kim ET, Gray JJ. Rosettaantibody: Antibody variable region homology modeling server. Nucleic Acids Res 2009; 37:W474-479; http://www.ncbi.nlm.nih.gov/pubmed/19458157; PMID:19458157; http://dx.doi.org/10.1093/nar/gkp387
- Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the mullerian inhibiting substance type ii receptor: A promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 2006; 5:2096-105; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16928831; PMID:16928831; http://dx.doi.org/10.1158/1535-7163.MCT-06-0115
- Kipriyanov SM, Moldenhauer G, Little M. High level production of soluble single chain antibodies in small-scale escherichia coli cultures. J Immunol Methods 1997; 200:69-77; http://www.ncbi.nlm.nih.gov/pubmed/9005945; PMID:9005945; http://dx.doi.org/10.1016/S0022-1759(96)00188-3
- Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, et al. Isolation of scfvs to in vitro produced extracellular domains of egfr family members. Cancer Biother Radiopharm 2005; 20:603-13; http://www.liebertonline.com/doi/abs/10.1089/cbr.2005.20.603?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16398612; http://dx.doi.org/10.1089/cbr.2005.20.603
- Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of her2-positive tumor xenografts with an iodine-124 labeled anti-her2 diabody. Cancer Res 2005; 65:1471-8; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15735035; PMID:15735035; http://dx.doi.org/10.1158/0008-5472.CAN-04-2008